Full Prescribing Information, Including BOXED WARNING
Read About Twirla
Agile Therapeutics Applauds Congressional Chairs’ Letter to Biden Administration Requesting Enforcement of Contraceptive Access Under Affordable Care Act
Agile Therapeutics Appoints Josephine Torrente to its Board of Directors
Agile Therapeutics Announces Pricing of $22,666,650 Underwritten Public Offering of Common Stock and Warrants
Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Warrants
Agile Therapeutics Announces Addition of Twirla® to a Preferred Drug Position on Medi-Cal Formulary
Agile Therapeutics Partners with Carli Lloyd, U.S. Women’s Soccer Star and Four-Time Olympian, to Bring Awareness to Women’s Health Topics
Agile Therapeutics to Participate in Upcoming Investor Conferences
Agile Therapeutics Partners with Telehealth Service, Pandia Health, to Increase Women’s Access to Twirla® (levonorgestrel and ethinyl estradiol) transdermal system
Agile Therapeutics Reports Second Quarter 2021 Financial Results
Our pipeline reflects our commitment to bringing women the healthcare choices they deserve. All current Agile Therapeutics product and product candidates use our proprietary Skinfusion® Technology.
Commitment. Passion. Drive.
These are the qualities that make us who we are, from the top down.
©2021 Agile Therapeutics®. All Rights Reserved.
View a snapshot of our consumer advertising